| Bethany Home Sioux Falls | |
| 1901 South Holly Avenue, Sioux Falls, South Dakota 57105 | |
| (605) 338-2351 | |
| Name | Bethany Home Sioux Falls |
|---|---|
| Location | 1901 South Holly Avenue, Sioux Falls, South Dakota |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 52 |
| Occupancy Rate | 74.81% |
| Medicare ID (CCN) | 435096 |
| Legal Business Name | Bethany Lutheran Home |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1023063856 |
| Organization Name | BETHANY LUTHERAN HOME |
| Doing Business As | BETHANY HOME SIOUX FALLS |
| Address | 1901 S Holly Ave, Sioux Falls, SD 57105 |
| Phone Number | 605-338-2351 |
News Archive
A team of American infectious disease and critical care experts is alerting colleagues caring for Ebola patients that how they remove their personal protective gear can be just as crucial as wearing it to prevent exposure to the deadly virus.
A report, prepared by a global leader for trusted human resources and related financial advice, products and services, finds that the addition of chiropractic care for the treatment of low back and neck pain will likely increase value-for-dollar in US employer-sponsored health benefit plans.
Infants who consumed soy-based formula as newborns had differences in some reproductive-system cells and tissues, compared to those who used cow-milk formula or were breastfed, according to a new study.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the unblinded results of the first of their 2 placebo-controlled double blind studies in volunteers with their anti-scarring agent RXI-109, a proprietary sd-rxRNA compound that has been shown in vitro and in animals to reduce mRNA for connective tissue growth factor.
Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), today announced positive top-line results from a pivotal, non-human primate study of its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) against an inhaled lethal dose of tularemia. A 14-day course of Restanza achieved a 100% survival rate at the doses tested. All of the ten animals in the study that received 16 mg/kg once-a-day of Restanza (approximate to a human dose of 300 mg) within 24 hours after exposure to a lethal dose of inhaled tularemia survived while only one of the ten animals that received placebo survived.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
A team of American infectious disease and critical care experts is alerting colleagues caring for Ebola patients that how they remove their personal protective gear can be just as crucial as wearing it to prevent exposure to the deadly virus.
A report, prepared by a global leader for trusted human resources and related financial advice, products and services, finds that the addition of chiropractic care for the treatment of low back and neck pain will likely increase value-for-dollar in US employer-sponsored health benefit plans.
Infants who consumed soy-based formula as newborns had differences in some reproductive-system cells and tissues, compared to those who used cow-milk formula or were breastfed, according to a new study.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the unblinded results of the first of their 2 placebo-controlled double blind studies in volunteers with their anti-scarring agent RXI-109, a proprietary sd-rxRNA compound that has been shown in vitro and in animals to reduce mRNA for connective tissue growth factor.
Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), today announced positive top-line results from a pivotal, non-human primate study of its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) against an inhaled lethal dose of tularemia. A 14-day course of Restanza achieved a 100% survival rate at the doses tested. All of the ten animals in the study that received 16 mg/kg once-a-day of Restanza (approximate to a human dose of 300 mg) within 24 hours after exposure to a lethal dose of inhaled tularemia survived while only one of the ten animals that received placebo survived.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $49579 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 17.92 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5.45 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 77.03 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.17 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 14.41 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 6.02 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 92.48 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 15.38 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 88.48 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 22.65 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 12.17 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 10.98 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 94.81 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 82.92 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 43.48 | 82.93 |
News Archive
A team of American infectious disease and critical care experts is alerting colleagues caring for Ebola patients that how they remove their personal protective gear can be just as crucial as wearing it to prevent exposure to the deadly virus.
A report, prepared by a global leader for trusted human resources and related financial advice, products and services, finds that the addition of chiropractic care for the treatment of low back and neck pain will likely increase value-for-dollar in US employer-sponsored health benefit plans.
Infants who consumed soy-based formula as newborns had differences in some reproductive-system cells and tissues, compared to those who used cow-milk formula or were breastfed, according to a new study.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the unblinded results of the first of their 2 placebo-controlled double blind studies in volunteers with their anti-scarring agent RXI-109, a proprietary sd-rxRNA compound that has been shown in vitro and in animals to reduce mRNA for connective tissue growth factor.
Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), today announced positive top-line results from a pivotal, non-human primate study of its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) against an inhaled lethal dose of tularemia. A 14-day course of Restanza achieved a 100% survival rate at the doses tested. All of the ten animals in the study that received 16 mg/kg once-a-day of Restanza (approximate to a human dose of 300 mg) within 24 hours after exposure to a lethal dose of inhaled tularemia survived while only one of the ten animals that received placebo survived.
› Verified 2 days ago
Avantara Norton Location: 3600 South Norton Avenue, Sioux Falls, South Dakota 57105 Phone: (605) 338-9891 | |
Good Samaritan Society Luther Manor Location: 1500 W 38th St, Sioux Falls, South Dakota 57105 Phone: (605) 336-1997 | |
Good Samaritan Society Sioux Falls Village Location: 3901 S Marion Rd, Sioux Falls, South Dakota 57106 Phone: (605) 361-3311 | |
Good Samaritan Society Sioux Falls Center Location: 401 West Second Street, Sioux Falls, South Dakota 57104 Phone: (605) 336-6252 | |
Avera Prince Of Peace Location: 4513 South Prince Of Peace Place, Sioux Falls, South Dakota 57103 Phone: (605) 322-5600 | |
Bethany Home Sioux Falls Location: 1901 South Holly Avenue, Sioux Falls, South Dakota 57105 Phone: (605) 338-2351 |